RecruitingPhase 3NCT06589804
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Studying Cancer of unknown primary site
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Siddharth ShethAlliance for Clinical Trials in Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 158 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Fremont - Rideout Cancer Center, Marysville, California, United States
- VA Palo Alto Health Care System, Palo Alto, California, United States
- UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States
- Memorial Hospital North, Colorado Springs, Colorado, United States
- Poudre Valley Hospital, Fort Collins, Colorado, United States
- Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, United States
- Lutheran Hospital - Cancer Centers of Colorado, Golden, Colorado, United States
- UCHealth Greeley Hospital, Greeley, Colorado, United States
- Medical Center of the Rockies, Loveland, Colorado, United States
- Mount Sinai Medical Center, Miami Beach, Florida, United States
- Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States
- Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States
- Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06589804 on ClinicalTrials.govOther trials for Cancer of unknown primary site
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07524114Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)University Health Network, Toronto
- RECRUITINGNANCT07283939Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment DelaysAlliance for Clinical Trials in Oncology
- RECRUITINGPHASE2NCT06995508Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO TrialRoswell Park Cancer Institute
- RECRUITINGPHASE1NCT06868433TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerEmory University
- RECRUITINGNANCT06662058Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or RadiationEmory University
- RECRUITINGPHASE2NCT06636734Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialEmory University
- RECRUITINGNANCT06644716[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary OriginErasmus Medical Center
- RECRUITINGPHASE1NCT05172245Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerNational Cancer Institute (NCI)